C
Celmatix
Harnessing the power of data and genomics to optimize medical decisions about fertility.
About Celmatix
Celmatix is a biotechnology company focused on advancing women's reproductive health through innovative solutions. Operating in the healthcare and biotechnology market, Celmatix serves patients, healthcare providers, and pharmaceutical companies. The company utilizes genomics and artificial intelligence (AI) to develop treatments for conditions such as ovarian senescence, polycystic ovary syndrome (PCOS), and primary ovarian insufficiency (POI). Celmatix's business model includes partnerships with leading pharmaceutical companies like Bayer and Evotec, as well as funding from organizations such as the Bill & Melinda Gates Foundation. Revenue is generated through collaborative discovery, development, and commercialization of new treatments, as well as through personalized reproductive medicine initiatives. The company collects and analyzes extensive biological and medical data to inform its research and development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- New York City, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 71.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Fertility, Analytics, Predictive Analytics, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Femtech
- Technology
- Big Data, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Dec 2019 | $6.5M | $26M | Undisclosed | — |
| EARLY VCOther financing | Apr 2019 | $8.8M | $35M | Undisclosed | — |
Growth signals
Latest recorded traffic for Celmatix is 270 monthly website visits, down 75.5% over the last three months. Celmatix's team declined 18.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Long Island Angel Network
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Celmatix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Celmatix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.